Oral Drug Delivery Videos

  1. Expanding Biologics Delivery Options Via Oral Devices With Biograil's Karsten Lindhardt 4/25/2025

    Large, complex molecules present significant challenges in the formulation and absorption of biologics-based therapies administered orally. In this episode of Supplier Horizons, host Tom von Gunden talks with CEO Karsten Lindhardt of oral platform technology developer Biograil about capsule-enclosed combination devices that offer patients convenience, safety, and effectiveness while bolstering patient compliance.

  2. Understanding The Global Regulatory Landscape For Combination Products 8/14/2025

    In this videocast episode, host Tom von Gunden discusses Chapter 14 of The Combination Products Handbook (CRC Press) with the book’s editor Susan Neadle, along with chapter coauthors Stephanie Goebel, Cherry Malonzo Marty, and Viky Verna. The group provides overviews of the commonalities and variances in regulatory definitions and guidances for combination products across global jurisdictions and agencies. 

  3. What Happened to CAPA (Corrective and Preventive Actions) Requirements? 7/11/2024

    Is CAPA still part of the requirements picture for the new QMSR? In this segment of the Drug Delivery Leader Live event New FDA QMSR: Its Role in Part 4 Compliance for Combination Products, consultant Ed Bills of Edwin Bills Consultant discusses changes in the treatment of corrective and preventive actions.

  4. Technology To Overcome Absorption Hurdles And Solubility Limitations 3/6/2024

    For poorly soluble drugs, overcoming absorption hurdles can hinder development. Explore a solution that empowers researchers to overcome solubility limitations and accelerate drug development.

  5. Halting HAE Attacks Via Oral Delivery With Pharvaris' Wim Souverijns And Stefan Abele 3/20/2025

    In this episode of Sit and Deliver, host Tom von Gunden talks with Chief Commercial Officer Wim Souverijns and Chief Technical Operations Officer Stefan Abele from Pharvaris, a developer of orally administered treatments for hereditary angioedema, or HAE.

  6. Future Of Pharma Packaging: Trends, Tech, And Patient Solutions 9/25/2025

    Explore how traditional and innovative pharmaceutical packaging formats improve patient adherence, support emerging therapies, and shape the future of drug delivery and treatment outcomes.

  7. Drug Delivery Self-Administration: The Rise Of The Epinephrine Autoinjector 5/23/2025

    In this segment of the Drug Delivery Leader Live online event, Innovations In Drug Delivery: Opportunities For Enhancing Familiar, Mature Approaches, Courtney Evans, principal consultant at Suttons Creek, comments on drug delivery technology advancements, particularly around the challenge of greater reliability. Her commentary begins with the market introduction of epinephrine autoinjectors and moves to more recent advances in nasal spray alternatives.

  8. Management Responsibility and the New QMSR 7/11/2024

    What is management’s responsibility in the implementation of approaches to the new QMSR? In this segment of the Drug Delivery Leader Live event New FDA QMSR: Its Role in Part 4 Compliance for Combination Products, consultant Laurie Auerbach of Compliance Prodigies underscores the criticality of management commitment to and engagement in the process.

  9. The Role Of Terminology In Regulating Combination Products 1/12/2026

    In this segment of the Drug Delivery Leader Live online event, Eying The Drug Delivery Regulatory Landscape: The 'Must See' Watch List For 2026, Chief Editor Tom von Gunden asks panelist Barr Weiner to describe the role of case study examples in defining and regulating combination products globally. Weiner makes the case for agreement about the science and technology being more important than commonality in terminology, Panelist Fran DeGrazio agrees.

  10. Becoming A Combination Product Development Organization 1/12/2026

    In this segment of the Drug Delivery Leader Live online event, Eying The Drug Delivery Regulatory Landscape: The 'Must See' Watch List For 2026, Chief Editor Tom von Gunden asks the panel to comment on regulatory challenges and considerations for traditional drug product pharma companies moving into combination product development. Patient centricity, device expertise, and supplier relationships are among the topics identified.